CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2022; 82(06): 619-626
DOI: 10.1055/a-1816-6700
GebFra Science
Original Article

Effect of Teriparatide on Subsequent Fracture and Bone Mineral Density in 47 Women with Pregnancy- and Lactation-associated Osteoporosis and Vertebral Fractures

Auswirkung von Teriparatid auf nachfolgende Frakturen und Knochendichte bei 47 Frauen mit schwangerschaftsassoziierter Osteoporose und Wirbelfrakturen
Peyman Hadji
1   Frankfurt Centre for Bone Health, Frankfurt, Germany
2   Philipps-University of Marburg, Marburg, Germany
,
Niki Mouzakiti
3   Dpt. of Obstetrics and Gynaecology, Centre for Ultrasound and Prenatal Medicine, Buergerhospital and Clementine Childrenʼs Hospital Frankfurt a. M., Dr. Senckenberg Foundation and Johann-Wolfgang-Goethe University of Frankfurt, Frankfurt, Germany
,
Ioannis Kyvernitakis
4   Dpt. Of Obstetrics and Prenatal Medicine, Asklepios Clinic Barmbek, University of Semmelweis, Hamburg, Germany
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Introduction Pregnancy- and lactation-associated osteoporosis (PLO) with predominantly vertebral fractures is a rare but severe disease which can occur in the last trimester of pregnancy or postpartum. The aim of the present study was to assess the impact of teriparatide on subsequent fractures and bone mineral density (BMD) in patients with PLO.

Materials and Methods A total of 47 patients with PLO and postpartum spinal fractures (mean: 4 fractures) undergoing treatment with teriparatide were investigated. The data collection period was set between 2006 and 2018. All patients received a subcutaneous injection of 20 µg teriparatide once a day for 24 months as well as individually adapted vitamin D supplementation. After 24 months of treatment, all women received no further treatment and either had regular menstrual cycles or took oral contraceptives. Fractures were confirmed by X-ray or MRI. Changes in BMD from baseline were examined using serial DXA measurements.

Results After 24 months of teriparatide treatment, we could demonstrate an increase in BMD at the lumbar spine, femoral neck and total hip of + 30.1%, + 11.7% and + 12.2% respectively (p < 0.001 for all). At 12 months after cessation of treatment, BMD remained stable compared to the 24-month measurements at the lumbar spine, femoral neck and total hip which showed non-significant changes of + 1.4%, + 2.6% and + 4.1% respectively. Out of the 47 patients with PLO with a mean of 4 existing fractures, 4 patients (7.8%) sustained a subsequent fracture, two after 3 – 5 months of treatment and two at > 6 months of treatment.

Conclusion 24 months of treatment with teriparatide in women with PLO and multiple vertebral fractures significantly increased BMD, predominantly BMD of the spine. As patients were premenopausal, there was no significant decrease in BMD in the following 12 months after cessation of treatment.

Zusammenfassung

Einleitung Schwangerschaftsassoziierte Osteoporose (PLO) mit Wirbelfrakturen ist eine seltene, aber ernste Erkrankung, die im letzten Trimenon oder nach der Geburt auftreten kann. Ziel dieser Studie war es, die Auswirkung von Teriparatid auf nachfolgend auftretende Frakturen sowie die Knochendichte (BMD) bei Patientinnen mit PLO zu evaluieren.

Material und Methoden Untersucht wurden insgesamt 47 Patientinnen mit PLO und postpartalen Wirbelfrakturen (Durchschnitt: 4 Frakturen), die mit Teriparatid behandelt wurden. Die Daten wurden zwischen 2006 und 2018 gesammelt. Alle Patientinnen erhielten einmal täglich eine subkutane Injektion von 20 µg Teriparatid über einen Zeitraum von 24 Monaten sowie eine individuell angepasste Supplementierung mit Vitamin D. Nach 24 Monaten Behandlung wurde die Behandlung ausgesetzt. Alle Frauen hatten entweder regelmäßige Menstruationszyklen oder oder nahmen orale Kontrazeptiva. Das Vorhandensein von Frakturen wurde entweder durch Röntgenuntersuchungen oder MRT bestätigt. Änderungen der Knochendichte-Ausgangswerte wurden mit DXA-Messungen festgestellt.

Ergebnisse Nach 24 Monaten Teriparatid-Behandlung wurde eine Zunahme der Knochendichte im Lendenwirbelbereich, am Schenkelhals und über die gesamte Hüfte in Höhe von + 30,1%, + 11,7% bzw. + 12,2% festgestellt (p < 0,001 für alle Werte). Zwölf Monate nach Einstellung der Behandlung war die Knochendichte stabil verglichen mit den Messungen an der Lendenwirbelsäule, an Schenkelhals und der gesamten Hüfte nach 24 Monaten; es wurden nichtsignifikante Änderungen in Höhe von + 1,4%, + 2,6% bzw. + 4,1% gemessen. Von den insgesamt 47 Patientinnen mit PLO und durchschnittlich 4 Frakturen erlitten 4 Patientinnen (7,8%) nach Beginn der Behandlung 1 Fraktur, davon 2 nach 3 – 5 Monaten Behandlung und 2 nach mehr als 6 Monaten Behandlung.

Schlussfolgerung Eine Behandlung mit Teriparatid über 24 Monate bei Frauen mit PLO und mehreren Wirbelfrakturen führt zu einer signifikanten Zunahme der Knochendichte, vor allem im Bereich der Wirbelsäule. Da alle Patientinnen noch prämenopausal waren, gab es keine signifikante Abnahme der Knochendichte 12 Monate nach Einstellung der Behandlung.

Key words

fracture osteoporosis - teriparatide - pregnancy - lactation

Schlüsselwörter

osteoporotische Frakturen - Teriparatid - Schwangerschaft - Stillzeit


Publikationsverlauf

Eingereicht: 04. November 2021

Angenommen nach Revision: 01. April 2022

Artikel online veröffentlicht:
03. Juni 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-1733
    CrossrefPubMedGoogle Scholar
  • 2 Nordin BE, Roper A. Post-pregnancy osteoporosis; a syndrome?. Lancet 1955; 268: 431-434
    CrossrefPubMedGoogle Scholar
  • 3 Winter EM, Ireland A, Butterfield NC. et al. Pregnancy and lactation, a challenge for the skeleton. Endocr Connect 2020; 9: R143-R157
    CrossrefPubMedGoogle Scholar
  • 4 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936
    CrossrefPubMedGoogle Scholar
  • 5 Lewiecki EM, Kendler DL, Kiebzak GM. et al. Special report on the official positions of the International Society for Clinical Densitometry. Osteoporos Int 2004; 15: 779-784
    CrossrefPubMedGoogle Scholar
  • 6 Loukadaki O, Tournis S, Gazi S. Clinical Case: Pregnancy lactation osteoporosis. Mediterr J Rheumatol 2017; 28: 161-163
    CrossrefPubMedGoogle Scholar
  • 7 Kovacs CS. Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery. Physiol Rev 2016; 96: 449-547
    CrossrefPubMedGoogle Scholar
  • 8 Ma YL, Cain RL, Halladay DL. et al. Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001; 142: 4047-4054
    CrossrefPubMedGoogle Scholar
  • 9 Kovacs CS, Ralston SH. Presentation and management of osteoporosis presenting in association with pregnancy or lactation. Osteoporos Int 2015; 26: 2223-2241
    CrossrefPubMedGoogle Scholar
  • 10 Miyamoto T, Miyakoshi K, Sato Y. et al. Changes in bone metabolic profile associated with pregnancy or lactation. Sci Rep 2019; 9: 6787
    CrossrefPubMedGoogle Scholar
  • 11 Wright EV, Naqvi AZ, Syed S. et al. Transient osteoporosis of the hip in pregnancy: the orthopaedic management of bilateral neck of femur fractures in the third trimester. BMJ Case Rep 2021; 14: e238659
    CrossrefPubMedGoogle Scholar
  • 12 Cerit ET, Cerit M. A case of pregnancy and lactation associated osteoporosis in the third pregnancy; robust response to teriparatide despite delayed administration. Bone Rep 2020; 13: 100706
    CrossrefPubMedGoogle Scholar
  • 13 Di Gregorio S, Danilowicz K, Rubin Z. et al. Osteoporosis with vertebral fractures associated with pregnancy and lactation. Nutrition 2000; 16: 1052-1055
    CrossrefPubMedGoogle Scholar
  • 14 Hadji P, Boekhoff J, Hahn M. et al. Pregnancy-associated transient osteoporosis of the hip: results of a case-control study. Arch Osteoporos 2017; 12: 11
    CrossrefPubMedGoogle Scholar
  • 15 Iwata A, Kanayama M, Oha F. et al. Effect of teriparatide (rh-PTH 1–34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study. BMC Musculoskelet Disord 2017; 18: 148
    CrossrefPubMedGoogle Scholar
  • 16 Kovacs CS. Osteoporosis presenting in pregnancy, puerperium, and lactation. Curr Opin Endocrinol Diabetes Obes 2014; 21: 468-475 DOI: 10.1097/MED.0000000000000102.
    CrossrefPubMedGoogle Scholar
  • 17 Aspenberg P, Genant HK, Johansson T. et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010; 25: 404-414
    CrossrefPubMedGoogle Scholar
  • 18 Hoshino M, Nakamura H, Terai H. et al. Factors affecting neurological deficits and intractable back pain in patients with insufficient bone union following osteoporotic vertebral fracture. Eur Spine J 2009; 18: 1279-1286
    CrossrefPubMedGoogle Scholar
  • 19 Kalder M, Hans D, Kyvernitakis I. et al. Effects of Exemestane and Tamoxifen treatment on bone texture analysis assessed by TBS in comparison with bone mineral density assessed by DXA in women with breast cancer. J Clin Densitom 2014; 17: 66-71
    CrossrefPubMedGoogle Scholar
  • 20 Hadji P, Imani P, Wuster C. et al. Comparison of dual-energy X-ray absorptiometry with six quantitative ultrasonometry devices in women with hip fractures. Climacteric 2015; 18: 411-418
    CrossrefPubMedGoogle Scholar
  • 21 Kyvernitakis I, Reuter TC, Hellmeyer L. et al. Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up. Osteoporos Int 2018; 29: 135-142
    CrossrefPubMedGoogle Scholar
  • 22 Qian Y, Wang L, Yu L. et al. Pregnancy- and lactation-associated osteoporosis with vertebral fractures: a systematic review. BMC Musculoskelet Disord 2021; 22: 926
    CrossrefPubMedGoogle Scholar
  • 23 OʼSullivan SM, Grey AB, Singh R. et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int 2006; 17: 1008-1012
    CrossrefPubMedGoogle Scholar
  • 24 Hadji P, Boekhoff J, Hahn M. et al. Pregnancy-associated osteoporosis: a case-control study. Osteoporos Int 2017; 28: 1393-1399
    CrossrefPubMedGoogle Scholar
  • 25 Butscheidt S, Tsourdi E, Rolvien T. et al. Relevant genetic variants are common in women with pregnancy and lactation-associated osteoporosis (PLO) and predispose to more severe clinical manifestations. Bone 2021; 147: 115911
    CrossrefPubMedGoogle Scholar
  • 26 Butscheidt S, Delsmann A, Rolvien T. et al. Mutational analysis uncovers monogenic bone disorders in women with pregnancy-associated osteoporosis: three novel mutations in LRP5, COL1A1, and COL1A2. Osteoporos Int 2018; 29: 1643-1651
    CrossrefPubMedGoogle Scholar
  • 27 Laroche M, Talibart M, Cormier C. et al. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int 2017; 28: 3135-3142
    CrossrefPubMedGoogle Scholar
  • 28 Lampropoulou-Adamidou K, Trovas G, Stathopoulos IP. et al. Case report: Teriparatide treatment in a case of severe pregnancy-and lactation- associated osteoporosis. Hormones (Athens) 2012; 11: 495-500
    CrossrefPubMedGoogle Scholar
  • 29 Cohen A, Kamanda-Kosseh M, Dempster DW. et al. Women With Pregnancy and Lactation-Associated Osteoporosis (PLO) Have Low Bone Remodeling Rates at the Tissue Level. J Bone Miner Res 2019; 34: 1552-1561
    CrossrefPubMedGoogle Scholar
  • 30 Hellmeyer L, Boekhoff J, Hadji P. Treatment with teriparatide in a patient with pregnancy-associated osteoporosis. Gynecol Endocrinol 2010; 26: 725-728
    CrossrefPubMedGoogle Scholar
  • 31 Lampropoulou-Adamidou K, Trovas G, Triantafyllopoulos IK. et al. Teriparatide Treatment in Patients with Pregnancy- and Lactation-Associated Osteoporosis. Calcif Tissue Int 2021; 109: 554-562
    CrossrefPubMedGoogle Scholar
  • 32 Choe EY, Song JE, Park KH. et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab 2012; 30: 596-601
    CrossrefPubMedGoogle Scholar
  • 33 Winarno AS, Kyvernitakis I, Hadji P. Successful treatment of 1–34 parathyroid hormone (PTH) after failure of bisphosphonate therapy in a complex case of pregnancy associated osteoporosis and multiple fractures. Z Geburtshilfe Neonatol 2014; 218: 171-173
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 34 Polat SB, Evranos B, Aydin C. et al. Effective treatment of severe pregnancy and lactation-related osteoporosis with teriparatide: case report and review of the literature. Gynecol Endocrinol 2015; 31: 522-525
    CrossrefPubMedGoogle Scholar
  • 35 Hong N, Kim JE, Lee SJ. et al. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis. Clin Endocrinol (Oxf) 2018; 88: 652-658
    CrossrefPubMedGoogle Scholar
  • 36 Lee S, Hong N, Kim KJ. et al. Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis. Calcif Tissue Int 2021; 109: 544-553
    CrossrefPubMedGoogle Scholar